EXACT Therapeutics AS announces the publication of its 2021 Annual Report

Oslo/London - April 27th 2022: EXACT Therapeutics AS ("EXACT-Tx", Euronext
Growth: EXTX), a clinical stage biopharmaceutical company with a mission to
enhance the therapeutic efficacy of medicines through ultrasound-mediated drug
delivery, today announces that its Board of Directors has approved the Annual
Report including the Annual Financial Statements for the year ended 31 December
2021. 
The Annual Report for 2021 is also available on the Company's website:
https://www.exact-tx.com/key-information

ENDS

For more information, please contact:

Dr Masha StrØmme, Executive Board Chair
EXACT Therapeutics 
Email: Masha@exact-tx.com

Dominic Moreland, CFO
EXACT Therapeutics 
Email: Dominic@exact-tx.com

Optimum Strategic Communications
Hollie Vile/ Manel Mateus/ Vici Rabbetts
Tel: +44 (0) 208 078 4357
Email: Exact@optimumcomms.com

About EXACT-Tx
EXACT-Tx is a Norwegian clinical-stage precision health company developing a
technology platform for targeted therapeutic enhancement - Acoustic Cluster
Therapy (ACT®). ACT® is a proprietary formulation of microclusters (PS101)
activated by ultrasound for enhanced drug targeting deployed in multiple
indications to enhance the therapeutic efficacy of medicines through the use of
ultrasound-mediated drug delivery, for patients across multiple diseases.
www.exact-tx.com

Forward looking statements
This announcement and any materials distributed in connection with this
announcement may contain certain forward-looking statements. By their nature,
forward-looking statements involve risk and uncertainty because they reflect the
Company's current expectations and assumptions as to future events and
circumstances that may not prove accurate. A number of material factors could
cause actual results and developments to differ materially from those expressed
or implied by this forward-looking statement.